Remove Clinical Pharmacology Remove Clinical Research Remove Compliance
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in November 2023

Agency IQ

What When it might happen Additional details FDA published a draft guidance document proposing a 180-day enforcement period for dietary supplement products to come into compliance with requirements that all New Dietary Ingredients be listed. Comments on the proposal closed on July 19. Once published, the 180-day amnesty period will start.

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in March and April 2024

Agency IQ

Start Date End Date Event Event Type Center 02/26/2024 02/26/2024 FDA/CDER and American Association of Pharmaceutical Scientists (AAPS) Hybrid Public Workshop Public CDER 02/27/2024 02/27/2024 FDA Oncology Center of Excellence Presents: Conversations on Cancer, Black History Month Program: “Real Talk: Our Stories as Black Oncologists at the FDA” Webcast (..)

FDA 40
article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in February and March 2024 (Updated)

Agency IQ

What When it might happen Additional details FDA published a draft guidance document proposing a 180-day enforcement period for dietary supplement products to come into compliance with requirements that all New Dietary Ingredients be listed. Comments on the proposal closed on July 19. Once published, the 180-day amnesty period will start.

FDA 40
article thumbnail

How Improving Diversity Can Benefit Clinical Trials

Alta Sciences

Regulatory organizations like Health Canada, the International Council for Harmonisation (ICH), and the European Medicines Agency (EMA) have long emphasized the importance of including diverse populations in clinical research. This minimizes the variability in data when a study goes hybrid and improves compliance and quality of data.